1. Home
  2. ULS vs VTRS Comparison

ULS vs VTRS Comparison

Compare ULS & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UL Solutions Inc.

ULS

UL Solutions Inc.

HOLD

Current Price

$90.10

Market Cap

18.2B

Sector

N/A

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$15.01

Market Cap

17.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ULS
VTRS
Founded
1894
1961
Country
United States
United States
Employees
N/A
30000
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.2B
17.2B
IPO Year
2023
2019

Fundamental Metrics

Financial Performance
Metric
ULS
VTRS
Price
$90.10
$15.01
Analyst Decision
Buy
Buy
Analyst Count
8
4
Target Price
$88.85
$13.50
AVG Volume (30 Days)
568.2K
8.3M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
0.66%
3.21%
EPS Growth
N/A
N/A
EPS
1.60
N/A
Revenue
$3,053,000,000.00
$14,299,900,000.00
Revenue This Year
$6.29
$4.41
Revenue Next Year
$5.67
$1.96
P/E Ratio
$54.94
N/A
Revenue Growth
6.38
N/A
52 Week Low
$58.79
$8.19
52 Week High
$94.04
$16.47

Technical Indicators

Market Signals
Indicator
ULS
VTRS
Relative Strength Index (RSI) 58.03 64.52
Support Level $77.01 $12.90
Resistance Level $92.55 $15.22
Average True Range (ATR) 2.55 0.40
MACD -0.25 0.10
Stochastic Oscillator 63.34 88.38

Price Performance

Historical Comparison
ULS
VTRS

About ULS UL Solutions Inc.

UL Solutions is a global leader specializing in a broad range of product testing, inspection, and certification services. UL Solutions is the for-profit branch out of three organizations under the UL Enterprise. TIC operations make up nearly all of UL Solutions' total revenue and are composed of two segments: industrial and consumer. UL Solutions' remaining business includes software and advisory, which complements its core TIC offerings. The firm operates globally.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: